Expert analysis and insight across the pharmaceutical industry. Explore reports covering market growth forecasts, epidemiology, pipeline assessments, competitive landscapes and more.
This report provides a data-driven view of the patient population affected by Obesity. It examines diagnosed incidence and prevalence, risk factors, demographic patterns and segmentation across leading healthcare markets, supporting long-range planning for weight management therapies, incretin-based treatments and emerging long-acting candidates.
United States, five major European markets, Japan and select emerging marketsView Report
This report provides a data-driven view of the patient population affected by Type 2 Diabetes. It examines diagnosed incidence and prevalence, risk factors, demographic patterns and segmentation across leading healthcare markets, supporting long-range planning for glucose-lowering agents, combination regimens and next-generation insulin approaches.
United States, five major European markets, Japan and select emerging marketsView Report
This report provides a data-driven view of the patient population affected by Type 1 Diabetes. It examines diagnosed incidence and prevalence, risk factors, demographic patterns and segmentation across leading healthcare markets, supporting long-range planning for immunomodulatory strategies, insulin delivery advances and cell-based approaches.
United States, five major European markets, Japan and select emerging marketsView Report
This report provides a data-driven view of the patient population affected by Alzheimer’s Disease. It examines diagnosed incidence and prevalence, risk factors, demographic patterns and segmentation across leading healthcare markets, supporting long-range planning for anti-amyloid antibodies, tau-targeting programs and symptomatic treatments.
United States, five major European markets, Japan and select emerging marketsView Report
This report provides a data-driven view of the patient population affected by Parkinson’s Disease. It examines diagnosed incidence and prevalence, risk factors, demographic patterns and segmentation across leading healthcare markets, supporting long-range planning for dopaminergic therapies, disease-modifying candidates and advanced delivery systems.
United States, five major European markets, Japan and select emerging marketsView Report
This report provides a data-driven view of the patient population affected by Multiple Sclerosis. It examines diagnosed incidence and prevalence, risk factors, demographic patterns and segmentation across leading healthcare markets, supporting long-range planning for high-efficacy disease-modifying therapies and progressive-stage treatments.
United States, five major European markets, Japan and select emerging marketsView Report
This report provides a data-driven view of the patient population affected by Epilepsy. It examines diagnosed incidence and prevalence, risk factors, demographic patterns and segmentation across leading healthcare markets, supporting long-range planning for anti-seizure medications, precision approaches and rare epilepsy syndromes.
United States, five major European markets, Japan and select emerging marketsView Report
This report provides a data-driven view of the patient population affected by Migraine. It examines diagnosed incidence and prevalence, risk factors, demographic patterns and segmentation across leading healthcare markets, supporting long-range planning for CGRP-targeting agents, acute therapies and preventive treatment innovation.
United States, five major European markets, Japan and select emerging marketsView Report
This report provides a data-driven view of the patient population affected by Amyotrophic Lateral Sclerosis. It examines diagnosed incidence and prevalence, risk factors, demographic patterns and segmentation across leading healthcare markets, supporting long-range planning for neuroprotective agents, gene-targeted therapies and biomarker-driven trials.
United States, five major European markets, Japan and select emerging marketsView Report
This report provides a data-driven view of the patient population affected by Huntington’s Disease. It examines diagnosed incidence and prevalence, risk factors, demographic patterns and segmentation across leading healthcare markets, supporting long-range planning for huntingtin-lowering strategies and symptomatic management options.
United States, five major European markets, Japan and select emerging marketsView Report
